Ncardia

Executive Summary

Ncardia is a private Netherlands-based biotechnology company founded in 2011, specializing in induced pluripotent stem cell (iPSC) technology. The company provides high-quality iPSC-derived cells, screening assays, and custom iPSC services to support drug discovery, safety pharmacology, and regenerative medicine. Positioned as a technology and service provider, Ncardia serves pharmaceutical and biotech companies developing novel therapies. With a focus on iPSC-derived cardiomyocytes, neurons, and hepatocytes, the company enables more predictive human-relevant assays, reducing reliance on animal models. Although financial details are undisclosed, Ncardia has likely raised venture capital to support its R&D and commercialization efforts. The company operates from Maastricht, Netherlands, and competes in the growing iPSC market, which is expanding due to demand for better disease modeling and drug screening tools. Ncardia's business model centers on product sales, licensing, and custom service agreements, aiming to become a key partner in the preclinical drug development pipeline.

Upcoming Catalysts (preview)

• Q4 2026Launch of new iPSC-derived hepatocyte product for liver toxicity screening70% success
• H2 2026Announcement of a strategic partnership with a top 10 pharma for drug discovery services60% success
• H1 2027Series B financing round to expand product portfolio and global sales50% success